Communique from EGM in Oncology Venture A/S
Hoersholm, Denmark, December 18, 2018 – at this time, a rare basic assembly in Oncology Venture A/S was held. A abstract of the resolutions adopted follows under. All resolutions had been adopted with the required majority of votes.
Election of latest members of the board of administrators
Niels Johansen resigned from the board of administrators and Duncan Moore and Sanjeevi Carani each earlier members of the Board of Oncology Venture Sweden AB had been elected as new members of the board of administrators of the corporate.
Resolution to authorize the board of administrators of the Company to extend the share capital
It was resolved to amend the articles of affiliation by renewing and increasing the present authorization to the board of administrators to extend the share capital of the corporate. It was resolved to authorize the board of administrators in the interval till December 17, 2023 to resolve to extend the corporate’s share capital in a number of points by as much as a complete nominal quantity of DKK 503,112. The improve of the corporate’s share capital shall be with out pre-emptive subscription rights for the present shareholders. The new shares shall be issued at a subscription worth decided by the board of administrators, which shall by no means be decrease than the market worth.
Resolution to authorize the board of administrators of the Company to concern warrants to traders
It was resolved to authorize the board of administrators in the interval till December 17, 2023 to, on a number of events, concern warrants to traders in the corporate entitling the holder to subscribe shares for a complete of as much as nominal worth of DKK 390,000 with out pre-emptive rights for the corporate’s shareholders. The new shares shall be issued at a subscription worth decided by the board of administrators, which shall by no means be decrease than the market worth.
Resolution to authorize the board of administrators of the Company to concern convertible bonds
It was resolved to authorize the board of administrators in the interval till December 17, 2023, a number of instances, with none pre-emptive subscription rights for the present shareholders, to resolve to lift loans for a complete quantity of as much as SEK 100,000,000 towards the issuance of convertible debt devices entitling the holder to subscribe for shares in the corporate and to impact the related capital will increase. The loans should be paid in money to the corporate. The board of administrators will lay down the precise phrases and situations for the convertible debt devices being issued below this authorization. Conversion might not happen at a worth, which is decrease than the market worth of the corporate’s shares.
For additional data, please contact:
For investor inquiries For media inquiries
Ulla Hald Buhl, IR & Communication Thomas Pedersen, Carrotize PR & Communications
E-mail: firstname.lastname@example.org E-mail: email@example.com
Telephone +45 21 70 10 49 Telephone +45 60 62 93 90
About Oncology Venture A/S
Oncology Venture A/S is engaged in the analysis and growth of anti-cancer medicine through its wholly-owned subsidiary, Oncology Venture Product Development ApS. Oncology Venture makes use of Drug Response Prediction – DRP® –to considerably improve the likelihood of success in scientific trials. DRP® has confirmed its capacity to supply a statistically important prediction of the scientific consequence from drug therapy in most cancers sufferers in 29 out of 37 scientific research that had been examined and is presently demonstrating promising outcomes in an ongoing part 2 examine prospectively utilizing LiPlaCis and its DRP® to trace, match and deal with sufferers with metastatic breast most cancers. The DRP® alters the chances in comparability with conventional pharmaceutical growth. Instead of treating all sufferers with a specific sort of most cancers, sufferers’ tumors genes are first screened, and solely the sufferers almost certainly to reply to the therapy might be handled. Via a extra well-defined affected person group, dangers and prices are decreased whereas the event course of turns into extra environment friendly.
The present OV product portfolio contains: LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate most cancers; 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast most cancers; dovitinib a submit part 3 product, which can enter Phase 2 trials for indications depending on additional Dovitinib-DRP evaluation of research accomplished by Novartis. 2X-111, a liposomal formulation of doxorubicin below manufacturing for Phase 2 in breast most cancers; irofulven is in Phase 2 in prostate most cancers; and APO010, an immuno-oncology product in Phase 1/2 for a number of myeloma.
Oncology Venture has spun out two firms as Special Purpose Vehicles: Oncology Venture U.S. Inc. (beforehand 2X Oncology Inc.), a US-based precision medication firm specializing in creating 2X-121 and 2X-111, and OV-SPV 2, a Danish firm that can take a look at and develop dovitinib. Oncology Venture A/S has an possession of 92% in Oncology Venture US and 55% of dovitinib with a possibility to amass additional 30%.
Learn extra at oncologyventure.com
Follow us on social media:
This announcement contains forward-looking statements that contain dangers, uncertainties and different components, lots of that are exterior of OV’s management and which might trigger precise outcomes to vary materially from the outcomes mentioned in the forward-looking statements. Forward-looking statements embrace statements regarding OV’s plans, aims, targets, future occasions, efficiency and/or different data that’s not historic data. All such forward-looking statements are expressly certified by these cautionary statements and another cautionary statements which can accompany the forward-looking statements. OV undertake no obligation to publicly replace or revise forward-looking statements to mirror subsequent occasions or circumstances after the date made, besides as required by regulation.
Norra Vallgatan 64, 211 22, Malmö, Sverige
Telefon: +46 40 615 14 10
This data is data that Oncology Venture A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The data was submitted for publication on December 18, 2018.